RxDoctor Payments Data

Virginia McNeill, NP

Gerontology · Northport, ALNPI 1194388587

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 567 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $4,196 and has fallen 95.4% since, to $191 in 2025. Among gerontology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,612in general payments, 2019–2025

Across 567 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Argenx US, Inc.$862
  • Novartis$823
  • CSL Behring$767
  • Takeda Pharmaceuticals U.S.A., Inc.$456
  • Johnson & Johnson$448
  • plus $6K from 33 others

What the payments were for

  • Food & beverage$10,612100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,612 in reported general payments places this provider in the 95th percentile of 143 gerontology providers in Alabama.

See all gerontology providers in Alabama

Medicare billing

Part B allowed, 2024
$10,923
Medicare patients
61
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant16$22,993
Rivastigmine26$4,857
Memantine Hcl46$1,365
Carbidopa-LevodopaCarbidopa/Levodopa38$1,075
Sertraline Hcl44$353
Bupropion Hcl SrBupropion Hcl16$301
Levetiracetam17$251
Methocarbamol19$193
Amitriptyline Hcl13$174
Donepezil Hcl35$172
Tizanidine Hcl24$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$1,530$22,99316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 gerontology providers in Alabama.

Other gerontology in Northport

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →